ERAS Jul 2024 2.500 call
| Previous close | 0.0500 |
| Open | 0.1500 |
| Bid | 0.1000 |
| Ask | 0.3500 |
| Strike | 2.50 |
| Expiry date | 2024-07-19 |
| Day's range | 0.1500 - 0.2000 |
| Contract range | N/A |
| Volume | |
| Open interest | 617 |
GlobeNewswireErasca Announces Strategic In-Licensing of RAS-Targeting Franchise
Pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 are potent, oral inhibitors with potential best-in-class profiles in RASm solid tumors Pipeline prioritization and workforce restructuring sharpens focus on programs targeting the highest unmet needs and with highest probability of success Priced concurrent $160 million equity offering Erasca to host conference call and webcast Friday, May 17, 2024 at 8:30 am ET SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERA
- GlobeNewswire
Erasca Announces Pricing of Underwritten Offering of Common Stock
SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the pricing of an underwritten offering of 86,486,486 shares of its common stock at a price of $1.85 per share. All of the shares to be sold in the offering are to be sold by Erasca. The gross proceeds to Erasca from the offering, before d
GlobeNewswireErasca Reports First Quarter 2024 Business Updates and Financial Results
Median OS of 13-14 months for naporafenib plus trametinib in pooled analysis of patients with NRASm melanoma Strengthened balance sheet with private placement financing from high-quality new and existing healthcare-focused investors Pro forma cash, cash equivalents, and marketable securities of $334 million is expected to fund operations into H2 2026 SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discover
